Valuation
- Market cap
- 71,003,000
- Revenue TTM
- $0
- Net income TTM
- $-22,400,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 279,900
- Avg volume
- 502,704
- Day's range
- $1.10 – $1.15
- Shares out
- 61,742,000
- Stochastic %K
- 50%
- Beta
- 0.27
- Analysts
- Sell
- Price target
- $12.00
Company profile
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 312 416 8592
- Website
- https://maiabiotech.com
- Address
- 444 West Lake Street, Suite 1700, Chicago, United States
Latest news
No headlines yet.
